Join to view full profile
9427 SW Barnes RdSte 595Portland, OR 97225
Phone+1 503-216-1150
Fax+1 503-216-1066
Dr. Cohan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown UniversityResidency, Neurology, 1973 - 1974
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Neurology, 1969 - 1971
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1968 - 1969
State University of New York Downstate Medical Center College of MedicineClass of 1968
Certifications & Licensure
OR State Medical License 1999 - 2027
DC State Medical License 1971 - 2000
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Start of enrollment: 2003 Dec 01
- Measurement of Relaxin Peptide in Multiple Sclerosis (MS) Start of enrollment: 2013 Sep 20
- MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- 1 citationsSafety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE s...Robert J Fox, Stanley Cohan, Yang Mao-Draayer, Bianca Weinstock-Guttman, Linda-Ali Cruz
Multiple Sclerosis. 2025-05-01 - 6 citationsCognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.Ralph Hb Benedict, Ludwig Kappos, Aaron Miller, Hans-Peter Hartung, James Overell
Multiple Sclerosis and Related Disorders. 2025-03-01 - 7 citationsMulti-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.Sergey A Kornilov, Nathan D Price, Richard Gelinas, Juan Acosta, Mary E Brunkow
Journal of the Neurological Sciences. 2024-12-15
Press Mentions
- Quality of Life Among Injectable and Oral Disease-Modifying Therapy Users in the Pacific Northwest Multiple Sclerosis RegistryDecember 4th, 2020
Daclizumab Beta May Be Superior to Interferon Beta on MS Disability ProgressionJanuary 8th, 2019
I Have MS and I’m Very LuckyMay 22nd, 2018
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:










